HAYWARD, Calif., Jan. 7, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the
appointment of Klara A. Dickinson as
Senior Vice President, Chief Regulatory Officer.
"We're fortunate to have Klara join our team as we enter this
phase of our product development efforts," said Paul F. Truex, Anthera's President and CEO. "Her
recent and highly relevant experience with the development and
eventual approval of novel therapies for underserved patient
populations will be indispensable as we advance Sollpura as a
treatment for exocrine pancreatic disorder in patients with cystic
fibrosis into a Phase 3 registration trial later this year.
Her leadership will also be instrumental as we enter the final
stages of development with blisibimod for both IgA Nephropathy and
Lupus."
"I'm excited to join Anthera during such important stages for
both Sollpura and blisibimod," said Ms. Dickinson. "I look forward
to sharing my regulatory expertise as we move forward with each of
our development programs."
Ms. Dickinson served as Senior Vice President of Regulatory
Affairs and Compliance at Hyperion Therapeutics Inc. from
October 2007 to July 2014. In that role, Ms. Dickinson led the
filing of the NDA and label negotiations for Hyperion Therapeutics'
initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for
chronic management of adult and pediatric patients >2 years of
age with urea cycle disorders (UCDs). Prior to Hyperion
Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and
was most recently Vice President, Regulatory Affairs and Healthcare
Compliance Officer from January 2004
to January 2007. In that role, Ms. Dickinson led the filing
of the NDA and label negotiations for CoTherix's initial product,
Ventavis ® (iloprost) Inhalation Solution. Prior to CoTherix,
Inc., Ms. Dickinson held various positions at biopharmaceutical
companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan,
Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory
Affairs Certification Board.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious and
life-threatening diseases, including lupus, lupus with
glomerulonephritis, IgA nephropathy, and exocrine pancreatic
insufficiency due to cystic fibrosis.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with the SEC,
including Anthera's Annual Report on Form 10-K for the year ended
December 31, 2013 and Quarterly
Report on Form 10-Q for the quarter ended September 30, 2014. Anthera disclaims any
intent or obligation to update any forward-looking statements,
whether because of new information, future events or otherwise,
except as required by applicable law.
CONTACT: Dennis Lutz of Anthera
Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-announces-appointment-of-klara-a-dickinson-as-senior-vice-president-chief-regulatory-officer-300017461.html
SOURCE Anthera Pharmaceuticals, Inc.